Egyesült Államok - angol - NLM (National Library of Medicine)

mcguff pharmaceuticals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 500 mg in 1 ml - ascor is vitamin c indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. limitations of use ascor is not indicated for treatment of vitamin c deficiency that is not associated with signs and symptoms of scurvy. none. use in specific populations 8.1 pregnancy 8.2 lactation 8.4 pediatric use 8.5 geriatric use 8.6 renal impairment 8.1 pregnancy risk summary there are no available data on use of ascor in pregnant women to inform a drug-associated risk of adverse developmental outcomes; however, use of ascorbic acid (vitamin c) has been used during pregnancy for several decades and no adverse developmental outcomes are reported in the published literature [see data]. there are dose adjustments for ascorbic acid (vitamin c) use during pregnancy [ see clinical considerations ]. animal reproduction studies have not been conducted with ascor. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations dose adjustments during pregnancy and post-partum period follow the u.s. recommended dietary allowances (rda) for pregnant women when considering use of ascor for treatment of scurvy [ see dosage and administration (2.3 )]. data human data there are no available data on use of ascor or another ascorbic acid injection in pregnant women. however, a published meta–analysis of randomized studies evaluating a large number of pregnant women who took oral ascorbic acid (vitamin c) (through diet and supplementation) at doses ranging from 500 to1000 mg/day (2.5 to 5 times the recommended daily intravenous dose, respectively) [ see dosage and administration (2.3) ] between the 9th and 16th weeks of pregnancy showed no increased risk of adverse pregnancy outcomes such as miscarriage, preterm premature rupture of membranes, preterm delivery or pregnancy induced hypertension when compared to placebo. these data cannot definitely establish or exclude the absence of a risk with ascorbic acid (vitamin c) during pregnancy. 8.2 lactation risk summary there are no data on the presence of ascorbic acid (vitamin c) in human milk following intravenous dosing in lactating women. ascorbic acid (vitamin c) is present in human milk after maternal oral intake. maternal oral intake of ascorbic acid (vitamin c) exceeding the u.s. recommended dietary allowances (rda) for lactation does not influence the ascorbic acid (vitamin c) content in breast milk or the estimated daily amount received by breastfed infants. there are no data on the effect of ascorbic acid (vitamin c) on milk production or the breastfed infant. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ascor and any potential adverse effects on the breastfed child from ascor or from the underlying maternal condition. follow the u.s. recommended dietary allowances (rda) for lactating women when considering use of ascor for treatment of scurvy [see dosage and administration (2.3) ]. 8.4 pediatric use ascor is indicated for the short term (up to 1 week) treatment of scurvy in pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. the safety profile of ascorbic acid in pediatric patients is similar to adults; however, pediatric patients less than 2 years of age may be at higher risk of oxalate nephropathy following ascorbic acid administration due to age-related decreased glomerular filtration [ see warnings and precautions (5.1 )]. ascor is not indicated for use in pediatric patients less than 5 months of age. 8.5 geriatric use glomerular filtration rate is known to decrease with age and as such may increase risk for oxalate nephropathy following ascorbic acid administration in elderly population [ see warnings and precautions (5.1 ) ]. 8.6 renal impairment ascor should be used with caution in scorbutic patients with a history of or risk of developing renal oxalate stones or evidence of renal impairment or other issues (e.g., patients on dialysis, patients with diabetic nephropathy, and renal transplant recipients). these patients may be at increased risk of developing acute or chronic oxalate nephropathy following high dose ascorbic acid administration [ see warning and precaution (5.1 ].

Egyesült Államok - angol - NLM (National Library of Medicine)

method pharmaceuticals, llc - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol succinate, d- (unii: lu4b53jyve) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with vitamins a, c and d. multi-vitamin drops with fluoride 0.25 mg also provides fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. the american academy of pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.25 mg of supplemental fluoride daily which is provided in a dose of 1 ml of multi-vitamin drops with fluoride 0.25 mg (see dosage and administration ). multi-vitamin drops with fluoride 0.25 mg supply significant amounts of vitamins a, c and d to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride.

Egyesült Államok - angol - NLM (National Library of Medicine)

method pharmaceuticals, llc - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol succinate, d- (unii: lu4b53jyve) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with vitamins a, c and d. multi-vitamin drops with fluoride and iron 0.25 mg also provides fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. the american academy of pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.25 mg of supplemental fluoride daily which is provided in a dose of 1 ml of multi-vitamin drops with fluoride 0.25 mg (see dosage and administration ). multi-vitamin drops with fluoride and iron 0.25 mg supply significant amounts of vitamins a, c and d to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride.

Egyesült Államok - angol - NLM (National Library of Medicine)

avkare, inc. - vitamin a acetate (unii: 3le3d9d6oy) (vitamin a - unii:81g40h8b0t), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4 - vitamin a 3080 [iu] - prenatal plus vitamin and mineral tablet is an tan-yellow colored, modified oval biconvex film coated tablet debossed g12 on one side, and provides 10 vitamins and 4 minerals to supplement the diet before, during and after pregnancy. each prenatal plus tablet contains: vitamin a (acetate and beta carotene) .......................................4000 i.u. vitamin c (ascorbic acid)……………………………………...........….120 mg vitamin d-3 (cholecalciferol)……………….....................................400 i.u. vitamin e (dl- alpha tocopheryl acetate)……………………...............22 mg thiamine (vitamin b-1 from thiamine mononitrate………............…1.84 mg riboflavin (vitamin b-2)………………………………………...............…3 mg niacin(niacinamide)……………………………………………………....  20 mg vitamin b-6 (pyridoxine hcl)…………………………………................10 mg folic acid……………………………………………………............

Egyesült Államok - angol - NLM (National Library of Medicine)

nephro-tech, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), pantothenic acid (unii: 19f5hk2737) (pantothenic acid - unii:19f5hk2737), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), folic acid (unii: 935e97boy8) (foli - ascorbic acid 60 mg - nephplex rx is a prescription folic acid supplement with additional nutrients for kidney dialysis patients. nephplex rx is a white, film-coated, oval shaped tablet.

Egyesült Államok - angol - NLM (National Library of Medicine)

taleos pharma - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium pantothenate (unii: - ascorbic acid 100 mg - this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

Málta - angol - Medicines Authority

alliance pharma (ireland) ltd - ascorbic acid, sodium ascorbate - chewable tablet - ascorbic acid 148.93 milligram(s) ; sodium ascorbate 176.74 milligram(s) - vitamins

Egyesült Államok - angol - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - infuvite pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite pediatric is contraindicated in patients who have: infuvite pediatric has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of non-pregnant women. animal reproduction studies have not been conducted with infuvite pediatric (multiple vitamins injection). infuvite pediatric has not been studied in nursing mothers. lactating women may have vitamin requirements that exceed those of non-lactating women. caution should be exercised when infuvite pediatric is administered to nursing mothers. infuvite pediatric is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years

Egyesült Államok - angol - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - infuvite adult is a combination of vitamins indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite adult is contraindicated in patients who have infuvite adult has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for their condition, because their vitamin requirements may exceed those of nonpregnant women. animal reproduction studies have not been conducted with infuvite adult. infuvite adult has not been studied in lactating women.lactating women should follow the u.s. recommended daily allowances for their condition, because their vitamin requirement may exceed those of nonlactating women. caution should be exercised when infuvite adult is administered to a nursing mother. safety and effectiveness in children below the age of 11 years have not been establish

Egyesült Királyság - angol - myHealthbox

crescent pharma ltd - ascorbic acid - tablets - 50mg - ascorbic acid (vit c), plain - for the treatment of scurvy. prophylactically in cases where deficiency might be expected to occur.